NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
50242-0918-86 | 50242-0918 | Atezolizumab | TECENTRIQ | 840.0 mg/14mL | Immunotherapy | Checkpoint Inhibitor | PD-L1 | Intravenous | Mar 8, 2019 | Mar 18, 2019 | In Use |
00469-4425-30 | 00469-4425 | ZOLBETUXIMAB | VYLOY | 20.0 mg/mL | Immunotherapy | Monoclonal Antibody | CLDN18.2 | Intravenous | Apr 24, 2025 | In Use | |
55566-1050-01 | 55566-1050 | Nadofaragene firadenovec-vncg | ADSTILADRIN | 300000000000.0 {VP}/mL | Immunotherapy | Gene Therapy | IFN⍺2b | Intravesical | Jul 1, 2023 | In Use | |
63459-0104-50 | 63459-0104 | Rituximab-abbs | Truxima | 10.0 mg/mL | Immunotherapy | Monoclonal Antibody | CD20 | Intravenous | May 4, 2020 | In Use | |
65219-0670-01 | 65219-0670 | Denosumab | BOMYNTRA | 70.0 mg/mL | Immunotherapy | Monoclonal Antibody | RANKL | Subcutaneous | Jun 30, 2025 | In Use | |
59572-0402-28 | 59572-0402 | Lenalidomide | Revlimid | 2.5 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | May 9, 2012 | In Use | |
59572-0405-28 | 59572-0405 | Lenalidomide | Revlimid | 5.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 3, 2009 | In Use | |
55513-0132-01 | 55513-0132 | trastuzumab-anns | Kanjinti | 420.0 mg/20mL | Immunotherapy | Monoclonal Antibody | HER2 | Intravenous | Jun 11, 2019 | In Use | |
55513-0141-01 | 55513-0141 | trastuzumab-anns | Kanjinti | 150.0 mg/7.15mL | Immunotherapy | Monoclonal Antibody | HER2 | Intravenous | Oct 28, 2019 | In Use | |
50242-0103-01 | 50242-0103 | polatuzumab vedotin | POLIVY | 30.0 mg/1.88mL | Immunotherapy | Drug Antibody Conjugate | CD79b | Intravenous | Sep 18, 2020 | In Use | |
00074-1044-01 | 00074-1044 | Telisotuzumab Vedotin | EMRELIS | 20.0 mg/mL | Immunotherapy | Drug Antibody Conjugate | c-MET | Intravenous | May 14, 2025 | In Use | |
00069-0238-01 | 00069-0238 | Rituximab-pvvr | Ruxience | 100.0 mg/10mL | Immunotherapy | Monoclonal Antibody | CD20 | Intravenous | Jan 23, 2020 | In Use | |
70710-1032-07 | 70710-1032 | LENALIDOMIDE | LENALIDOMIDE | 10.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sep 12, 2022 | In Use | |
61314-0228-94 | 61314-0228 | Denosumab | WYOST | 120.0 mg/1.7mL | Immunotherapy | Monoclonal Antibody | RANKL | Subcutaneous | Jun 2, 2025 | In Use | |
61314-0240-63 | 61314-0240 | Denosumab | JUBBONTI | 60.0 mg/mL | Immunotherapy | Monoclonal Antibody | RANKL | Subcutaneous | Jun 2, 2025 | In Use | |
73535-0208-01 | 73535-0208 | Tafasitamab-cxix | MONJUVI | 200.0 mg/5mL | Immunotherapy | Monoclonal Antibody | CD19 | Intravenous | Aug 5, 2020 | Nov 30, 2025 | In Use |
49281-0880-03 | 49281-0880 | BACILLUS CALMETTE-GUERIN SUBSTRAIN CONNAUGHT LIVE ANTIGEN | THERACYS | 81.0 mg/3mL | Immunotherapy | Biological Response Modifier | Live Vaccine | Intravesical | Jul 22, 2011 | May 8, 2017 | No Longer Used |
83444-0301-10 | 83444-0301 | Cosibelimab | UNLOXCYT | 300.0 mg/5mL | Immunotherapy | Checkpoint Inhibitor | PD-L1 | Intravenous | Jun 30, 2025 | In Use | |
00004-0350-39 | 00004-0350 | Peginterferon alfa-2a | Pegasys | 180.0 ug/mL | Immunotherapy | Cytokine | Interferon | Subcutaneous | Oct 16, 2002 | Sep 1, 2009 | No Longer Used |
72606-0038-01 | 72606-0038 | Denosumab-bmwo | Osenvelt | 120.0 mg/1.7mL | Immunotherapy | Monoclonal Antibody | RANKL | Subcutaneous | Jul 2, 2025 | In Use | |
55513-0207-01 | 55513-0207 | Bevacizumab-awwb | MVASI | 400.0 mg/16mL, 400.0 mg/16mL | Immunotherapy | Monoclonal Antibody | VEGFR | Intravenous | Jun 1, 2018 | In Use | |
57894-0450-01 | 57894-0450 | Teclistamab | TECVAYLI | 90.0 mg/mL | Immunotherapy | Monoclonal Antibody | BCMA, CD3 | Subcutaneous | Oct 25, 2022 | In Use | |
83654-0105-01 | 83654-0105 | Penpulimab | Penpulimab | 100.0 mg/10mL | Immunotherapy | Monoclonal Antibody | PD-1 | Intravenous | Apr 23, 2025 | In Use | |
50242-0088-01 | 50242-0088 | ADO-Trastuzumab Emtansine | Kadcyla | 20.0 mg/mL, 20.0 mg/mL | Immunotherapy | Drug Antibody Conjugate | HER2 | Intravenous | Feb 22, 2013 | In Use | |
31722-0261-21 | 31722-0261 | LENALIDOMIDE | LENALIDOMIDE | 20.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | May 11, 2023 | In Use |
Found 11748 results — Export these results